Table 1.
Baseline characteristics of the pooled, HOPE-3, and JUPITER study populations
| Baseline characteristics | Overall | HOPE 3 | JUPITER |
|---|---|---|---|
| Number of subjects randomized | 30 507 (100.0) | 12 705 (100.0) | 17 802 (100.0) |
| Age in years, mean (SD) | 65.96 (7.19) | 65.72 (6.38) | 66.13 (7.72) |
| Male, n (%) | 17 832 (58.45) | 6831 (53.77) | 11 001 (61.80) |
| Ethnicity, n (%) | |||
| Asian | 6524 (21.39) | 6241 (49.12) | 283 (1.59) |
| Caucasian | 15 229 (49.92) | 2546 (20.04) | 12 683 (71.25) |
| Black | 2449 (8.03) | 225 (1.77) | 2224 (12.49) |
| Hispanic or Latin American | 5757 (18.87) | 3496 (27.52) | 2261 (12.70) |
| Other | 546 (1.79) | 197 (1.55) | 349 (1.96) |
| BMI, kg/m2, median(IQR) | 27.6 (24.7–31.1) | 26.7 (24.1–29.7) | 28.4 (25.3–32.0) |
| Baseline systolic blood pressure, mmHg, median(IQR) | 136.0 (126.0–146.5) | 137.5 (128.5–147.5) | 134.0 (124.0–145.0) |
| Baseline diastolic blood pressure, mmHg, median(IQR) | 80.0 (75.0–88.0) | 82.0 (75.5–88.0) | 80.0 (75.0–87.0) |
| HDL, mg/dL, median(IQR) | 46.4 (38.6–56.8) | 43.6 (36.2–52.1) | 49.0 (40.0–60.0) |
| LDL, mg/dL, median(IQR) | 113.0 (97.0–126.0) | 127.0 (103.9–151.0) | 108.0 (94.0–119.0) |
| High sensitivity C-Reactive protein, mg/L, median(IQR) | 3.4 (2.1–6.0) | 2.0 (1.0–4.0) | 4.3 (2.8–7.1) |
| Hypertension, n (%) | 15 022 (49.25) | 4814 (37.89) | 10 208 (57.37) |
| Current smoking, n (%) | 5434 (17.82) | 2614 (20.58) | 2820 (15.85) |
| Anti-platelet therapy, n (%) | 4472 (14.66) | 1393 (10.96) | 3079 (17.30) |
| History of cancer, n (%) | 1065 (3.49) | 153 (1.20) | 912 (5.12) |
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.